メリーランド州における多発性骨髄腫の臨床試験
メリーランド州内の拠点で、多発性骨髄腫に関する25件の研究が参加者を募集しています。
メリーランド州内の都市
公式研究テキスト（英語）
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
- National Institutes of Health Clinical Center, Bethesda
被験者募集中第1相
18歳〜120歳 · 全性別 · 2026/10/02更新 · NCT06904066Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
- National Institutes of Health Clinical Center, Bethesda
被験者募集中観察研究
18歳〜120歳 · 全性別 · 2026/09/28更新 · NCT02682667Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
- National Institutes of Health Clinical Center, Bethesda
被験者募集中第2相
18歳〜72歳 · 全性別 · 2026/09/28更新 · NCT03412877Tissue Collection for Studies of Lymph Cancer
- National Institutes of Health Clinical Center, Bethesda
被験者募集中観察研究
18歳以上 · 全性別 · 2026/09/28更新 · NCT01676805A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Johns Hopkins Hospital, Baltimore
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07518186Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
- American Oncology Partners, PA dba The Center for Cancer and Blood Disorders, Bethesda
被験者募集中第4相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07609940A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- University of Maryland School of Medicine, Baltimore
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07258511A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Johns Hopkins University School of Medicine JHUSOM, Baltimore
- Center for Cancer and Blood Disorders, Bethesda
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT05552222Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
被験者募集中早期第1相
18歳以上 · 全性別 · 2026/09/24更新 · NCT0639845718F-Fluciclovine PET/CT in Multiple Myeloma
- National Institutes of Health Clinical Center, Bethesda
被験者募集中第2相
18歳〜120歳 · 全性別 · 2026/09/22更新 · NCT06103838Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Johns Hopkins Asthma & Allergy Center, Baltimore
- American Oncology Partners, PA dba The Center for Cancer and Blood Disorders, Bethesda
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/21更新 · NCT07648264Collection of Tissue Samples for Cancer Research
- Johns Hopkins University, Baltimore
- National Institutes of Health Clinical Center, Bethesda
被験者募集中観察研究
2 Months · 全性別 · 2026/09/16更新 · NCT00900198A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
- University of Maryland | Greenebaum Cancer Center, Baltimore
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/09更新 · NCT06980480A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma
- Maryland Oncology Hematology, Columbia
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/04更新 · NCT07637578A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
- GSK Investigational Site, Bethesda
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/25更新 · NCT07227311Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Baltimore
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/14更新 · NCT07764978A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
- University of Maryland Greenbaum Comprehensive Cancer Center, Baltimore
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/12更新 · NCT07280013A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Maryland Oncology Hematology - Silver Spring /ID# 268562, Silver Spring
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/13更新 · NCT05650632Integrated Cancer Repository for Cancer Research
- Northwest Hospital, Randallstown
- William E. Kahlert Regional Cancer Center, Westminster
被験者募集中観察研究健康なボランティア歓迎
19歳〜110歳 · 全性別 · 2026/06/29更新 · NCT02012699Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
- The Center for Cancer and Blood Disorders (CCBD), Bethesda
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/06/24更新 · NCT04068597Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Greater Baltimore Medical Center, Baltimore
被験者募集中第3相
全年齢 · 全性別 · 2026/06/10更新 · NCT05561387Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- Greenebaum Cancer Center UM of MD, Baltimore
- John Hopkins, Baltimore
被験者募集中第3相
18歳以上 · 全性別 · 2026/06/04更新 · NCT05243797Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
- Maryland Oncology Hematology, Columbia
被験者募集中第2相
18歳以上 · 全性別 · 2026/04/22更新 · NCT05972135A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Sibley Memorial Hospital, Baltimore
- University of Maryland, Baltimore
- Johns Hopkins Main Center, Baltimore
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/03/24更新 · NCT04988555A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
- Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center, Baltimore
被験者募集中第1/2相
18歳以上 · 全性別 · 2025/09/05更新 · NCT05372354ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。